HONG KONG, Oct 2, 2024 – (ACN Newswire) – Recently, Everest Medicines has revealed another favorable advancement. The business’s lead item, NEFECON, as the just in-disease IgA nephropathy (IgAN) treatment, hasactually been consistedof in the “KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)” (hereinafter referred to as the “New Guidelines (Draft)”), advising treatment with a 9-month course of NEFECON for clients who are at danger of progressive kidney function loss with IgAN (2B). This considerable turningpoint additional strengthens Everest Medicines’ management in the treatment of IgAN and brings brand-new hope to IgAN clients worldwide.
NEFECON Ushering in a New Era of Standardized Treatment of IgA Nephropathy
According to the New Guidelines, NEFECON is the just treatment to date tested to lower levels of pathogenic kinds of IgA and IgA immune complexes. The addition of NEFECON in the New Guidelines Draft strengthens NEFECON as the first-line foundation in the treatment of IgAN, ushering in a brand-new period of standardized treatment. With the impending release of China’s first-ever IgAN standards, NEFECON is anticipated to be advised as the first-line treatment for IgAN clients at danger of illness development, more enhancing its essential function in scientific practice.
According to Everest Medicines’ current monetary reports, NEFECON hasactually produced RMB 167.3 million in sales income simply over a month after its industrial launch and veryfirst prescription in mainland China in May 2024, demonstrating strong market need. NEFECON hasactually been commercially introduced in mainland China, Macau, and Singapore, and has likewise been authorized in Hong Kong. The New Drug Application (NDA) of NEFECON hasactually been accepted in South Korea, signaling consistent development in worldwide commercialization.
In the 2nd half of 2024, Everest Medicines will continue to promote the sales of NEFECON in mainland China and other areas in the Asia-Pacific, while